H.R. 1672

119th CongressIn committee

Maintaining Investments in New Innovation Act

Maintaining Investments in New Innovation Act

Sponsored by Donald G. Davis (Democrat-NC-1)

Healthcare & Public Health

Cosponsors

46

Actions

3

Roll calls

0

Amendments

0

Related bills

0

Actions

Feb 27, 2025 · Library of Congress

Introduced in House

Feb 27, 2025 · Library of Congress

Introduced in House

Feb 27, 2025 · House floor actions

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Latest activity

Activity

July 2026

Lobbying reported · Biotechnology Innovation Organization · Jul 21

Biotechnology Innovation Organization reported 2nd Quarter (Apr 1 - June 30) lobbying for Biotechnology Innovation Organization — $2,360,000

Lobbying reported · Alnylam Pharmaceuticals · Jul 20

Alnylam Pharmaceuticals reported 2nd Quarter (Apr 1 - June 30) lobbying for Alnylam Pharmaceuticals — $450,000

BillsH.R. 1672 H.R. 4993

Lobbying reported · Forbes-Tate · Jul 20

Forbes-Tate reported 2nd Quarter (Apr 1 - June 30) lobbying for Ionis Pharmaceutical — $30,000

Lobbying reported · Splitoak Strategies · Jul 20

Splitoak Strategies reported 2nd Quarter (Apr 1 - June 30) lobbying for Alnylam Pharmaceuticals — $60,000

Lobbying reported · Todd Strategy Group · Jul 20

Todd Strategy Group reported 2nd Quarter (Apr 1 - June 30) lobbying for Alnylam Pharmaceuticals — $60,000

Lobbying reported · Dla Piper LLP (US) · Jul 20

Dla Piper LLP (US) reported 2nd Quarter (Apr 1 - June 30) lobbying for Novartis — $60,000

BillsH.R. 1492 H.R. 1672 S. 832

Lobbying reported · Venable · Jul 20

Venable reported 2nd Quarter (Apr 1 - June 30) lobbying for Association Of Black Cardiologists — $30,000

BillsH.R. 307 H.R. 1672 H.R. 7417 S. 3944

Lobbying reported · Brownstein Hyatt Farber Schreck · Jul 20

Brownstein Hyatt Farber Schreck reported 2nd Quarter (Apr 1 - June 30) lobbying for Novartis — $90,000

Lobbying reported · Forbes-Tate · Jul 20

Forbes-Tate reported 2nd Quarter (Apr 1 - June 30) lobbying for Novartis — $50,000

BillsH.R. 1672 H.R. 3037 S. 832 S. 1500

Lobbying reported · Amgen · Jul 20

Amgen reported 2nd Quarter (Apr 1 - June 30) lobbying for Amgen — $2,440,000

Lobbying reported · The ALS Association · Jul 20

The ALS Association reported 2nd Quarter (Apr 1 - June 30) lobbying for The ALS Association — $30,000

Lobbying reported · Avenue Solutions · Jul 20

Avenue Solutions reported 2nd Quarter (Apr 1 - June 30) lobbying for Genentech USA — $50,000

BillsH.R. 1492 H.R. 1672 H.R. 4299

Lobbying reported · Novartis · Jul 20

Novartis reported 2nd Quarter (Apr 1 - June 30) lobbying for Novartis — $1,410,000

Lobbying reported · Harmony Biosciences · Jul 20

Harmony Biosciences reported 2nd Quarter (Apr 1 - June 30) lobbying for Harmony Biosciences — $180,000

BillsH.R. 1414 H.R. 1492 H.R. 1672 S. 832

Lobbying reported · BGR Government Affairs · Jul 20

BGR Government Affairs reported 2nd Quarter (Apr 1 - June 30) lobbying for Novartis — $60,000

Lobbying reported · Tiber Creek Group · Jul 19

Tiber Creek Group reported 2nd Quarter (Apr 1 - June 30) lobbying for Alnylam Pharmaceuticals — $60,000

Lobbying reported · Tiber Creek Group · Jul 18

Tiber Creek Group reported 2nd Quarter (Apr 1 - June 30) lobbying for Tiber Creek Health Strategies, Inc. (on Behalf Of Eli Lilly And Company) — $60,000

BillsH.R. 1492 H.R. 1672

Lobbying reported · Ionis Pharmaceuticals · Jul 17

Ionis Pharmaceuticals reported 2nd Quarter (Apr 1 - June 30) lobbying for Ionis Pharmaceuticals — $150,000

BillsH.R. 1262 H.R. 1414 H.R. 1672 S. 932

Lobbying reported · Todd Strategy Group · Jul 17

Todd Strategy Group reported 2nd Quarter (Apr 1 - June 30) lobbying for Novartis — $60,000

BillsH.R. 1492 H.R. 1672 H.R. 5376 S. 832 S. 3131

Lobbying reported · Corcoran Partners · Jul 16

Corcoran Partners reported 2nd Quarter (Apr 1 - June 30) lobbying for Novartis — $50,000